Loss of NF1 Expression in Human Endothelial Cells Promotes Autonomous Proliferation and Altered Vascular Morphogenesis

Anshika Bajaj, Qing-fen Li, Qingxia Zheng, Kevin Pumiglia

Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York, United States of America

Abstract

Neurofibromatosis is a well known familial tumor syndrome, however these patients also suffer from a number of vascular anomalies. The loss of NF1 from the endothelium is embryonically lethal in mouse developmental models, however little is known regarding the molecular regulation by NF1 in endothelium. We investigated the consequences of losing NF1 expression on the function of endothelial cells using shRNA. The loss of NF1 was sufficient to elevate levels of active Ras under non-stimulated conditions. These elevations in Ras activity were associated with activation of downstream signaling including activation of ERK, AKT and mTOR. Cells knocked down in NF1 expression exhibited no cellular senescence. Rather, they demonstrated augmented proliferation and autonomous entry into the cell cycle. These proliferative changes were accompanied by enhanced expression of cyclin D, phosphorylation of p27\(^{KIP}\), and decreases in total p27\(^{KIP}\) levels, even under growth factor free conditions. In addition, NF1-deficient cells failed to undergo normal branching morphogenesis in a co-culture assay, instead forming planar islands with few tubules and branches. We find the changes induced by the loss of NF1 could be mitigated by co-expression of the GAP-related domain of NF1 implicating Ras regulation in these effects. Using doxycycline-inducible shRNA, targeting NF1, we find that the morphogenic changes are reversible. Similarly, in fully differentiated and stable vascular-like structures, the silencing of NF1 results in the appearance of abnormal vascular structures. Finally, the proliferative changes and the abnormal vascular morphogenesis are normalized by low-dose rapamycin treatment. These data provide a detailed analysis of the molecular and functional consequences of NF1 loss in human endothelial cells. These insights may provide new approaches to therapeutically addressing vascular abnormalities in these patients while underscoring a critical role for normal Ras regulation in maintaining the health and function of the vasculature.

Introduction

Mutations in the NF1 gene cause Neurofibromatosis type 1, an autosomal dominant disease that affects approximately 1 in 3000 individuals, making it one of the most common inherited genetic disorders [1]. NF1 has variable clinical manifestations. Most commonly observed changes include alterations in skin pigmentation (café au-lait spots as well as freckling) and the presence of benign and malignant nerve sheath tumors termed neurofibromas [1]. Importantly, a significant clinical manifestation of NF1 disease includes vascular disease. Patients with NF1 disease make up a significant portion of all those patients presenting with renal artery stenosis and early-onset cerebral vascular disease [2] and cardiovascular disease is a significant contributor to premature death in NF1 patients, particularly among younger patients. One study suggested that vasculopathy was over seven times more likely to occur in NF1 patients under 30 compared to their unaffected peers [3].

NF1 is clinically associated with a pleiotropic array of vascular abnormalities including stenosis, malformations, aneurysms, and hypertension. As a consequence these patients show a markedly elevated risk of cerebrovascular accidents [2]. Previous studies in mice have suggested an important role of smooth muscle cells [4] and bone marrow cells [5] in neointimal hyperplasia, inflammation and exaggerated response to injury including enhanced angiogenesis. However little is currently known about factors contributing to vascular malformations and the role of endothelial cells in regulating these changes. In addition, the endothelium is critically poised to regulate blood vessel formation, vascular tone, inflammation, as well as coagulation, thus a better understanding of the role of NF1 in regulating the function of the vascular endothelium may be critical to understanding many facets of this disease and reducing its morbidity.

Previous studies support the notion that NF1 has a critical role in the vascular endothelium. Deletion of NF1 from the vascular
endothelium results in embryonic lethality [6] and NF1 haploinsufficient mice show exaggerated angiogenic responses [7]. As NF1 is a Ras-GTPase activating protein, changes in Ras activation are often associated with the loss of NF1 and data have been published suggesting that shRNA mediated knockdown of NF1 can augment growth factor mediated Ras activation and downstream signaling in endothelial cells [8]. NF1 is a large protein, however, with other signaling effects, including changes in cAMP and mTOR, which can be Ras-independent [9]. We have recently published that activation of Ras in primary endothelial cells is sufficient to drive a pro-survival, pro-proliferative phenotype that disrupts normal vascular morphogenesis [10]. It is unclear if loss of NF1 is sufficient to enhance basal activation of Ras and initiate cellular responses in the absence of additional growth factor signaling. We conducted these studies to determine if the loss of NF1 is sufficient to initiate cellular signaling and alter endothelial cell function, to determine the role of Ras and other cellular signals acting downstream of NF1, and to evaluate how these changes affect the behavior of endothelial cells in a complex microenvironment.

**Results**

**Knockdown of NF1 in Primary Endothelial Cells Activates Ras and Downstream Signaling**

To generate endothelial cells lacking neurofibromin a shRNA against NF1 was cloned into pSIREN-RetroQ-ZsGreen retroviral expression vector, as previously described [9] allowing stable knockdown of neurofibromin both at the protein (Fig. 1A) and mRNA levels (not shown). Primary cells have previously demonstrated growth arrest in response to the loss of NF1 [11]. To minimize potential confounding senescence effects, to regulate expression, and also to safeguard against RNAi mediated off-target effects, a different NF1 knockdown sequence was cloned into a lentiviral pTRIPZ vector that permits inducible knockdown of the protein in the presence of 0.5 μg/mL doxycycline whereas no knockdown was seen in the absence of doxycycline (Fig. 1B). Using both types of cells we examined the levels of active Ras in quiescent cells. Knockdown of NF1 in human endothelial cells using the inducible miR-based shRNA results in increased levels of active Ras under basal conditions (Fig. 1C). Similarly, stable knockdown of NF1 also results in enhanced levels of Ras-GTP (Figure S2), even following several passages suggesting limited down-regulation or cellular compensation of this response. The enhanced levels of Ras-GTP were sufficient to trigger downstream signaling, as knockdown of NF1 resulted in enhanced activation of ERK, PI-3'-Kinase/AKT (Fig. 1D), even in the absence of any added growth factors. Another important signaling network linked to tumors and cells lacking NF1 is the mTOR signaling pathway [12,13]. It has been shown that activation of mTOR pathway in neurofibromatous tumor cell lines is essential for neurofibroma formation [14]. As the role of NF1 in regulating mTOR signaling in endothelial cells is unknown, we investigated this by examining the phosphorylation of ribosomal S6, a substrate of the TORC1 activated kinase, S6K. We found loss of NF1, even the absence of added growth factors, sufficient to stimulate mTORC1/S6K signaling. Similar effects were observed with both the inducible and the stable knockdown, suggesting little temporal or kinetic differences between the constructs or approaches (Figs. 1D and S2). These data provide evidence that knockdown of the Ras-GAP NF1 in human endothelial cells is sufficient to elevate cellular GTP-Ras levels and activate downstream signaling in the absence of added growth factors.

**Cellular Proliferation in Endothelial Cells Lacking NF1**

Down-regulation of signaling is part of a feedback response that results in replicative arrest in primary fibroblasts. However, we see no evidence of signal dampening in endothelial cells lacking NF1 even after prolonged culturing. To determine if the chronic activation of Ras and the related signaling results in replicative senescence, we examined several aspects of cellular growth. Initially, we evaluated population doublings, often used to monitor oncogene-induced senescence. In contrast to the effects observed following NF1-loss in fibroblasts [11], we found no signs of growth arrest in NF1-knockdown cells, rather they showed enhanced proliferative capacity (Fig. 2A). Given the enhanced long-term proliferative capacity of NF1-knockdown cells and the previous report that NF1-knockdown could enhance VEGF-induced proliferation, we next sought to determine if NF1 was sufficient to induce endothelial cell proliferation in the absence of growth factors. As shown in Fig. 2B, even in the absence of added mitogenic factors, endothelial cells lacking NF1 expression demonstrated enhanced entry into S-phase of the cell cycle as measured by BrdU incorporation. The enhanced proliferation was accompanied by upregulation of cyclin D levels, enhanced phosphorylation of p27KIP, and a corresponding decrease in levels of total p27 (Fig. 2C). Thus, the signaling induced by the loss of NF1 is sufficient to stimulate DNA synthesis as a consequence of cyclin D induction and the loss of the Cyclin-dependent kinase inhibitor, p27KIP.

**Loss of NF1 is Associated with Altered Vascular Morphogenesis**

NF1 patients are known to have several distinct types of vascular anomalies associated with the disease, including vascular malformations. At this point it is unclear if this is the result of effects arising in endothelial cells or as a consequence of an altered and pro-angiogenic microenvironment. The altered proliferative control seen upon the loss of NF1 might contribute to altered morphogenic responses by human endothelial cells. To test this we utilized a co-culture assay where human endothelial cells in the presence of human primary fibroblasts will typically proliferate for a cycle or two followed by a cessation of proliferation and the formation of branched networks of endothelial cell tubules that contain patent lumens [10,15,16]. When we performed this assay we found that endothelial cells lacking NF1 had an altered morphogenic response. In lieu of forming elongated and branched networks, these cells tended to form planar, sheet like structures which showed few elongations and branches, as if an essential signal to “differentiate” into vascular structures was compromised (Fig. 3). Identical phenotypes were seen whether we used constitutive shRNA (pSiren) knockdown or the inducible miR-based construct (TripZ).

**Effects on Endothelial Cells Following the Loss of NF1 are a Consequence of Ras Activation**

The loss of NF1 is sufficient to activate cellular Ras. However, NF1 is a large protein with several alternative signaling paradigms through which it can affect cell function in a Ras-independent manner, including changes in cAMP signaling [9,17]. Therefore, we sought to determine if the effects we were seeing were the result of Ras activation. To test this we co-infected endothelial cells with inducible lentiviral vectors to knockdown NF1 and then re-express the GAP-related domain of NF1 (GRD) in order to “rescue” the Ras GAP functions of NF1 (this domain is outside the targeted region). Purified cells were obtained by two-color sorting (Red; TRIP-Z (NF1-KD) co-expressed RFP; Green; pSLIK (GRD) co-
As both vectors are tet-inducible, induction of knockdown also induces the "rescue" phenomenon in the cells co-infected with the GRD expressing virus. As shown in Fig. 4, the expression of the GRD reverses the Ras activation seen following the loss of NF1, returning it to basal levels. This is accompanied by a similar reversal of the autonomous proliferation (Fig. 4B) that the loss of NF1 promotes. Expression of GRD also reduced the enhanced phosphorylation of p27 that is seen following the loss of NF1 with a coincident stabilization of this protein (Fig. 4C).

We also used these cells to determine if Ras activity was responsible for the hyperplastic morphogenic responses we observed. As shown in Fig. 5A, co-expression of the GRD reverses the abnormal morphogenesis, with cells forming nicely branched and elongating networks when the GRD domain of Ras is co-expressed. These same cells were used to explore the reversibility of this phenotype. As shown in Fig. 5A, if the NF1-kD cells are allowed to form the hyperplastic structures for 14 days (a time at which normal endothelial cell networks have stabilized) and then the Dox is removed (to cease expression of the silencing shRNA), normal looking tubular branching structures emerge over the next 14 days. We also performed the converse experiment, where normal vessel-like structures were allowed to form and stabilize over 14 days (Fig. 5B). As Dox was added to induce the knockdown of NF1, vessel-like structures begin to thicken and fuse,
Figure 3. Loss of NF1 expression results in abnormal vascular morphogenesis. Top Panel - Primary endothelial cells infected with non-targeting pSIREN lentivirus (Control) or one directed toward knockdown of NF1 (NF1-KD). These cells were plated with primary fibroblasts in an admixed co-culture. After 14 days, endothelial cells were visualized by the vector expressed GFP. Bottom Panel - Endothelial cells infected with TRIPZ-Control or NF1miR-shRNA, were plated in co-culture with primary fibroblasts in the presence of doxycycline to induce expression of shRNA and RFP. Vascular structures were visualized at day 14 using RFP co-expressed in the endothelial cells.

doi:10.1371/journal.pone.0049222.g003

Figure 4. Enhanced proliferation following the loss of NF1 is a consequence of Ras activation. HUVECs were double infected with vectors coding for inducible NF1 knockdown shRNA and inducible expression of the GAP-related domain (GRD) of NF1 or empty vector. Cells were incubated for 24 h in the presence of 0.5 μg/ml doxycycline to induce expression of NF1 shRNA as well as the co-infected cDNA (GRD or empty). Control cells are cultured in the absence of doxycycline to suppress expression of and cDNA. After 24 h in the presence or absence of doxycycline, cells were switched to serum-free medium. (A) Cells were analyzed for the presence of active Ras using GST-pull down. Total Ras was used to insure equivalent protein in the input lysates. (B) BrdU incorporation was measured 24 h after changing to serum and growth factor free conditions. Data represents the averages from triplicate determinations and error bars represent standard error of the mean. (**p<0.01 compared to Control; # p<0.01 compared to NF1-kd. (C) Lysates prepared under the conditions described above were probed for changes in phosphorylation of p27 and total p27 levels by western blotting. ERK was monitored as a loading control. All experiments were replicated in an independently generated set of doubly infected cells.

doi:10.1371/journal.pone.0049222.g004
suggesting that malformed vascular structures can arise, even from quiescent endothelial cells. In cells “rescued” by coordinate expression of the GRD, vessel morphology remained intact and unchanged throughout the experimental manipulations. Collectively these data strongly argue that maintenance of appropriate levels of Ras activation are critical for vascular morphogenesis both in developing vessels and in established vascular networks.

**mTORC1 Activity is Essential for Endothelial Cell Proliferation and Abnormal Morphogenesis Following the Loss of NF1**

We next sought to determine the mechanisms required for the autonomous proliferation seen in response to the loss of NF1 and the accompanying activation of Ras. Given the emerging role of mTOR-related signaling in other aspects of NF1 disease, we were interested in the role of this enzyme [18,19,20]. We used the minimal concentrations of inhibitors required to effectively inhibit Ras-related signaling back to basal levels and evaluated the effects on cellular signaling. We found we could effectively inhibit ERK activation with no significant effects on the S6 activation or AKT activation (Fig. 6A). Proliferation was completely inhibited by inhibition of MAPK, as was the induction of cyclin D1 (data not shown), consistent with previous results from our lab that have consistently found an obligatory role for MAPK signaling in the proliferative response to activated Ras and growth factors in human endothelial cells [10,21,22], as well as those previously reported by Munchhof et al. [8]. The effects of PI-3-kinase inhibition were difficult to interpret, as inhibition of this signal also partially inhibited mTORC1 activation, likely explaining the intermediate and variable effect we observed with this inhibitor in proliferation assays (data not shown). However we found that at low doses of rapamycin (0.1 ng/ml), the NF1 mediated activation of AKT and ERK were unaffected while the NF1 mediated S6-phosphorylation was completely inhibited (Figs. 6A and S2). This dose of rapamycin was also sufficient to completely abrogate the proliferative response observed with the loss of NF1 expression. These data suggest an unexpected obligatory contribution of this pathway to the enhanced proliferation following suppression of NF1 expression. We next investigated the role mTORC1 in regulating two known modulators of endothelial cell cycle progression, Cyclin D1 and the phosphorylation of the corresponding cyclin dependent kinase inhibitor, p27Kip1 [23]. We find the induction of cyclin D and the phosphorylation of p27 is strongly affected by low dose rapamycin. Collectively these data suggest that the proliferative response we observe in endothelial cells with reduced NF1 expression is highly sensitive to inhibition by rapamycin which seems to act at least in part by suppressing cyclin D induction and the phosphorylation of p27.

As cells lacking NF1 induce a hyperplastic phenotype in coculture, we reasoned that this abnormal morphogenesis might be altered by low dose rapamycin. To test this, control and NF1-kd cells were co-cultured with primary fibroblasts, with or without low doses of rapamycin (Fig. 7). We found that in control endothelial cells the presence of rapamycin inhibited the number of tube-like structures; however the general characteristics of these branching networks were similar to untreated cells. Interestingly, in the NF1-kd cells, the sheet like phenotype was not present, rather the cells underwent normal branching morphogenesis, indicating that the blunting of mTORC1 signaling and endothelial cell proliferation was able to restore a normal phenotype to these cells.

**Discussion**

Our data strongly support a critical role for NF1 in the regulation of the vascular endothelium. These findings are in agreement with previous studies done in developmental models whereby the endothelial specific deletion of NF1 resulted in embryonic lethality. These data also agree with the data of Munchhof et al. [8], who found that knocking down of expression in endothelial cells augmented VEGF and FGF signaling and induced angiogenesis. Importantly our data extend this previous work in several critical areas both conceptually and mechanistically.

Notably, our data demonstrate that the loss of NF1 is sufficient to induce activation of Ras and initiate downstream signaling. This suggests that NF1 doesn’t just play a passive role in dampening Ras activation but rather is an active regulator of GTP-Ras accumulation. The loss of NF1 triggers the accumulation of Ras-GTP even under serum and growth factor-free conditions. The resulting accumulation of Ras-GTP is sufficient to initiate changes in cell behavior, including entry into the cell cycle and enhanced growth rates under mitogenic conditions. Importantly, we find no evidence of the senescence associated with the loss of NF1 in other cell types [11]. This finding is consistent with our previous findings showing a lack of senescence following expression of activated H-Ras. The changes in Ras-related signaling result in a gross perturbation of the endothelial cell vasculogenic program. Under co-culture conditions, normal primary endothelial cells stop growing, elongate, and form interconnected tubes; NF1-kd cells however, continue to maintain at least a partially proliferative phenotype and fail to branch and form tubular structures reliably. To our knowledge this is the first report that the loss of NF1 is sufficient to alter the morphogenic program of endothelial cells. This finding may help to shed light on the underlying cause of a least some of the vascular anomalies seen in some NF1 patients and may provide an in vitro model to study the molecular basis for these vascular defects.

It is noteworthy that the alteration of the morphogenic phenotype appears to be quite plastic. Under conditions where the vessel structures are malformed, a return of normal Ras regulation permits at least a partial normalization. Similarly even in stable vessel structures, the loss of NF1 and accompanying Ras activation results in the emergence of an altered phenotype. These data suggest that in NF1 patients, the acquisition of an additional mutation or epigenetic silencing of the remaining copy of NF1 might be sufficient to trigger Ras activation, autonomous proliferation and abnormal vessel formation – even in post-developmental quiescent vasculature. This data begins to explain the high frequency of moyamoya disease, arteriovenous malformations and possibly even aneurysms in the NF1 patient population. The finding that the Ras-GAP, RASA1 (p120-GAP), is mutated in several distinct vascular anomalies [24,25] including capillary malformation-arteriovenous malformations and Vein of Galen aneurysms supports this hypothesis, though it is currently unclear if the loss of RASA1 is sufficient to result in Ras activation. Recent data investigating the role of RASA1 in the endothelium of adult mice suggests that loss of RASA1 does result in abnormal morphlogy and lymphatic endothelial proliferation. However the activation of Ras and Ras-related signaling, along with the abnormal vascular phenotype were dependent upon coincident VEGFR3 signaling [26]. Current experiments are determining if the homozygous loss of NF1 in the post-natal vasculature is sufficient to trigger Ras signaling and vascular anomalies, particularly in a haploinsufficient microenvironment which is known to be pro-angiogenic [7].
NF1 Is Critical for Endothelial Cell Regulation

A

Day 14
Induced

NF1kd

NF1kd + GRD

Day 28
Uninduced

Media Change
- Dox

B

Day 14
Uninduced

NF1kd

NF1kd + GRD

Day 28
Induced

Media Change
+ Dox
Our data directly addressed the role of Ras in the endothelial cell regulation by NF1. While some cell types have been reported to have important Ras-independent functions of NF1 [27,28,29], our data suggest that alteration in Ras signaling is essential for the effects seen upon loss of NF1 in endothelial cells. We found that all of the phenotypes and signaling changes observed following the loss of NF1 were rescued by re-expression of the GAP-related domain of NF1 and the restoration of Ras regulation. However it is currently unclear if there is isoform specificity to the Ras activation seen following the loss of NF1 or if particular isoforms are linked to the phenotypic manifestations. Moreover we cannot rule out that other signaling changes are also taking place and contributing to the observed phenotypes.

We find that loss of NF1 triggered several Ras-related signaling pathways including activation of PI-3'-kinase and activation of mTOR signaling. The activation of mTOR was obligatory for the autonomous proliferation triggered by the loss of NF1. The proliferative dependency appears to arise out of mTOR-dependent phosphorylation of p27 leading to its degradation as well as induction of cyclin D1 which has previously been implicated in NF1 tumors [30]. Previous studies in our lab have determined that p27 degradation is an essential step in endothelial progression to S-Phase [23]. Our data do not address whether mTORC1 is directly phosphorylating p27, however we did not find any significant inhibition of either AKT or ERK (two enzymes known to phosphorylate p27) by the low dose of rapamycin we employed. It
is interesting to note that activation of mTOR has been associated with cutaneous vascular malformations [31]. The sensitivity of the NF1-kd endothelial cell proliferation and the normalization of the vascular morphogenesis following treatment with low-dose rapamycin in our assays suggest that “Rapalogy” currently in clinical trials as anti-tumor medications may be an effective management tool for certain types of vascular dysfunction in NF1 patients. In addition, it seems likely that these patients may be well-positioned to benefit from other currently approved vasculoprotective therapeutics, e.g., statins which can dampen both Ras and mTOR signaling [32,33] as well as metformin which activates AMPK signaling [34] to dampen mTOR.

**Materials and Methods**

**Ethics Statement**

Parents and legal guardians of donors provided consent that discarded tissue could be used for research purposes. The collection and use of tissue samples was evaluated and approved by the Institutional Review Board of Albany Medical Center. It was not considered Human subjects research under 45 CFR (Basic HHS Policy for Protection of Human Research Subjects) part 46 because, (1) the specimens were not collected specifically for the currently proposed research project and (2) the investigator(s) cannot readily ascertain the identity of the individual(s), consistent with the guidelines set forth by the Office of Human Research Protection of the US Federal Government.

**Cell Culture**

HUVECs (Human Umbilical Vein Endothelial Cells) were purchased from Cascade Biologics (Portland, Oregon, USA) or Lifeline Cell Technologies (Fredrick MD, USA). Cells were cultured as previously described [21]. Cells were made quiescent by incubation in serum free MCDB-131 supplemented with 1% penicillin/streptomycin and 2 mM L-glutamine (SF), where noted. Stimulation was performed with complete growth media. Primary fibroblasts were isolated from human foreskins provided as de-identified, discarded tissue from neonatal circumcision procedures at Albany Medical Center and grown in DMEM containing 10% FBS and 1% penicillin/streptomycin.

**Western Blotting**

Western blotting analysis used the following antibodies: mouse anti-pERK (Santa Cruz Biotechnology), rabbit anti-ERK2 (Santa Cruz Biotechnology), rabbit anti-NF1 (Bethyl Laboratories), rabbit anti-p27 (Santa Cruz Biotechnology), rabbit anti-phospho-p27 (Zymed), rabbit anti-pS6, rabbit anti-pAKT, mouse anti-cyclin D1, mouse anti-pan Ras (Oncogene Research, Calbiochem). All antibodies were used at a dilution of 1:1000 overnight at 4°C. Other conditions were the same as described in [21] except...
exposures were captured on a Kodak 4000 MM imager. All figures are representative of at least three independent experiments. Quantification was performed by using volume measurements from the KODAK imager for the band of interest and normalizing to the volume of the loading control (ERK2) for that lane. Data is the mean of three experiments and error bars represent the standard error of the mean. Statistical analysis was performed using students t-test or in some cases ANNOVA with a Bonferroni correction for multivariable conditions.

**Plasmid Construction**

To stably knockdown NF1 expression in HUVECs a shRNA sequence targeting NF1 (5’gattcGGACACAATGAGATTA-GATTTTCTCAGAGAATACTAACTTCATTGGTCCATTTGAGAGCCTG3’ sense strand) and (5’aattcACGCGTAAAGAGGAGCAGAGATATGAGATTAGATTTCCTCAGAGAAATCTAACTTCCATTGTGTTCCAG3’ antisense strand) into the RNAi-Ready pSIREN-RetroQ-ZsGreen retroviral expression vector from Clontech. The shRNA sequences were synthesized by Operon and had a Mmal restriction site in the hairpin loop region with BamHI and EcoRI cut overhangs for cloning. The oligonucleotides were annealed and ligated into the BamHI/EcoRI cut pSIREN-ZsGreen according to the “Knockout RNAi Systems User Manual” from Clontech. The same annealed shRNAs were ligated into the BamHI/EcoRI cut pSIREN-RetroQ-DsRed-Express vector to make a knockdown vector expressing red fluorescent protein. A Negative Control shRNA annealed oligonucleotide provided by Clontech was ligated similarly into the pSIREN-RetroQ-ZsGreen to make a control vector. Inducible knockdown of NF1 was achieved using a lentiviral pTRIPZ vector from Open Biosystems carrying the V2THS.200806 sequence for knocking down NF1. Schematics of these vector constructs are shown in Supplementary Fig. S1. To make a lentivector expressing the gap related domain (GRD) of NF1 the MSCV-puro-GRD-V5 plasmid was purchased from Addgene. A BglII/NotI fragment carrying the GRD was ligated into BamHI/NotI cut pEN_TRE2 [10]. The Tet promoter along with NF1-GRD was then put into the Gateway compatible destination vector pSLIK-Venus [35] using an LR-Clonase™ reaction resulting in the pSLIK-GRD-Venus plasmid.

**Production and Infection with Retroviruses and Lentiviruses**

The pSIREN-RetroQ-ZsGreen lentiviral vector carrying a negative control or a NF1 shRNA was transfected into retroviral packaging PhoenixA cells [36] using Lipofectamine 2000 reagent. The media from the transfected cells was sterile filtered through a 0.4 μM filter and the viral supernatant was used to infect low passage HUVECs in the presence of 5 μg/mL of polybrene. The HUVECs underwent a second round of infection in a similar manner after 24 h. The infection efficiency was 70–80% and a pure population of infected cells was obtained by flow cytometry. The infected cells were sorted by fluorescence-activated cell sorter (FACS) and sorted cells were used for experiments. With both the retroviral and lentiviral vectors, three independent infections were performed on three independent endothelial cell cultures in order to insure representative results.

**Measurement of DNA Synthesis and Growth Assays**

Endothelial cells were serum starved for 24 h, after which the complete growth media (GM) was added as a mitogenic stimulus for 16 h. Measurements of BrdU incorporation were performed as previously described [22]. In some cases indicated doses of Rapamycin were added to the cells at the time of serum starvation. Growth assays were conducted as described previously [38]. Population doublings were calculated using the formula: Population Doublings = Log(Final cell number/Initial cell number)/ Log2. Cumulative population doublings represent the sum of population doublings from all previous passages.

**Co-culture Assay**

This assay was performed as previously described [15] with modifications as we have previously reported [10]. Cells were typically tracked using the expression of fluorescent markers introduced during genetic modification. In some cases, cells were stained live with a FITC-tagged UEA-1 lectin (Sigma-Aldrich) or fixed in 3.7% formaldehyde and visualized with UEA-1 lectin.

**Supporting Information**

Figure S1 Schematic representation of NF1 knockdown constructs. (TIF)

Figure S2 Knockdown of NF1 by pSiren activates Ras and cellular signaling. (A) Cells infected with the pSiren vector targeting a control sequence or NF1 (NF1-kl) were analyzed by western blotting for the expression of NF1 using ERK2 as a loading control (upper panels). Cell lysates were also probed for active Ras using GTP pull-down experiments using anti-Ras immunoblotts (lower panels). GTP-Ras represents Ras bound to GST-Raf beads. Levels of total Ras in the input lysate were used to insure similar levels of lysate loading onto the beads. (B) Cell lysates from pSiren infected cells expressing control or NF-kl shRNAs were analyzed for presence of signals known to be downstream of active Ras and for sensitivity to treatment with low doses of the signal transduction inhibitors indicated using immunoblotting. ERK2 is used as a loading control to insure equivalent cellular lysate. Quantification of several similar experiments is shown in Figure 6A. (TIF)

**Acknowledgments**

The authors would like to thank Dr. Peter Vincent and Dr. Harold Singer for critical reading of the manuscript.

**Author Contributions**

Conceived and designed the experiments: AB Q-FL KP. Performed the experiments: AB Q-FL QZ. Analyzed the data: AB Q-FL QZ KP. Contributed reagents/materials/analysis tools: AB Q-FL. Wrote the paper: AB Q-FL KP.
NF1 Is Critical for Endothelial Cell Regulation

References

1. McClatchey AI (2007) Neurofibromatosis. Annu Rev Pathol 2: 191–216.
2. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, et al. (2002) Cardiovascular disease in neurofibromatosis 1: report of the NCI Cardiovascular Task Force. Genet Med 4: 105–111.
3. Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68: 1110–1118.
4. Xu J, Ismat FA, Wang T, Yang J, Epstein JA (2007) NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response. Circulation 116: 2148–2156.
5. Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, et al. (2010) Genetic and cellular evidence of vascular inflammation in neurofibromatosis-deficient mice and humans. J Clin Invest 120: 859–876.
6. Guder AD, Zhu Y, Ismat FA, Liu MM, Yamauchi Y, et al. (2003) NF1 has an essential role in endothelial cells. Nat Genet 33: 75–79.
7. Wu M, Wallace MR, Muir D (2006) NF1 haploinsufficiency augments angiogenesis. Oncogene 25: 2297–2303.
8. Munchhof AM, Li F, White HA, Mead LE, Krier TR, et al. (2006) Neurofibromatosis-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum Mol Genet 15: 1838–1869.
9. Dasgupta B, Dagan LI, Gutmann DH (2003) The neurofibromatosis 1 gene product neurofibromin regulates pinitary adenylyl cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 23: 8949–8954.
10. Bajaj A, Zheng QX, Adam A, Vincent P, Pumiglia K (2010) Activation of endothelial Ras signaling bypasses senescence and causes abnormal vascular morphogenesis. Cancer Res 70: 3803–3812.
11. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, et al. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10: 459–472.
12. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH (2005) Protein tyrosine phosphatase alpha is essential for NF1-associated malignancies. Cancer Res 65: 2755–2760.
13. Johannesen CM (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. PROC NATL ACAD SCI 102: 8573–8578.
14. Johannesen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56–62.
15. Hazrati F, Cohen C, Fried L, Arbiser J (2007) Mammalian target of Rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5: 233–236.
16. Endres M, Laufs U (2004) Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2790–2791.
17. Prinz V, Endres M (2011) Statins and stroke: prevention and beyond. Curr Opin Neurol 24: 75–80.
18. Eerola I, Bajaj LM, Mulliken JB, Burrows PE, Dompmartin A, et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56–62.
19. Lapinski PE, Kwon S, Lubeck BA, Wilkinson JE, Srinivasan RS, et al. (2012) RASA1 induces a proangiogenic phenotype in primary endothelial cells. Hum Mol Genet 15: 1838–1869.
20. Ma J, Li M, Hock J, Yu X (2012) Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1. J Orthopaedic Res 30: 144–152.
21. Meadors KN, Bryant P, Pumiglia K (2001) Vascular endothelial growth factor induction of the angiogenic phenotype requires Rac activation. J Biol Chem 276: 49289–49298.
22. Meadors KN, Bryant P, Vincent PA, Pumiglia KM (2004) Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23: 192–200.
23. Bryant P, Zheng Q, Pumiglia K (2006) Focal adhesion kinase controls cellular levels of p27/Kip1 and p21/Cip1 through Skp2-dependent and -independent mechanisms. Mol Cell Biol 26: 4201–4213.
24. Eerola I, Bajaj LM, Mulliken JB, Burrows PE, Dompmartin A, et al. (2008) Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73: 1240–1249.
25. Revenu N, Bajaj LM, Mulliken JB, Enolras O, Cordisco MR, et al. (2008) Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Human Mutation 29: 959–965.
26. Schnei F, Cohen C, Fried L, Arbiser J (2007) Mammalian target of Rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5: 233–236.
27. Endres M, Laufs U (2004) Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2790–2791.
28. Prinz V, Endres M (2011) Statins and stroke: prevention and beyond. Curr Opin Neurol 24: 75–80.
29. Eerola I, Bajaj LM, Mulliken JB, Burrows PE, Dompmartin A, et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56–62.
30. Shirazi F, Cohen C, Fried L, Arbiser J (2007) Mammalian target of Rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5: 233–236.
31. Endres M, Laufs U (2004) Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2790–2791.
32. Prinz V, Endres M (2011) Statins and stroke: prevention and beyond. Curr Opin Neurol 24: 75–80.
33. Eerola I, Bajaj LM, Mulliken JB, Burrows PE, Dompmartin A, et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56–62.
34. Schnei F, Cohen C, Fried L, Arbiser J (2007) Mammalian target of Rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5: 233–236.
35. Endres M, Laufs U (2004) Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2790–2791.
36. Prinz V, Endres M (2011) Statins and stroke: prevention and beyond. Curr Opin Neurol 24: 75–80.
37. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463–8471.
38. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p21WAF1/Cip1. Cell 88: 563–602.